TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference

Rhea-AI Summary

TScan Therapeutics, focusing on T-cell receptor therapies for cancer, will have CEO David Southwell join a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Conference on October 5, 2021, at 2:00 p.m. ET. The chat will be accessible via live webcast on the company's website, with an archived replay available afterward. TScan is developing innovative treatments, including TSC-100 and TSC-101, targeting hematologic malignancies and various solid tumors.

WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, President and Chief Executive Officer, will participate in a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 2:00 p.m. ET.

A live webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website following the event.

About TScan Therapeutics, Inc.

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Contacts

Media Contact:
David Rosen
Argot Partners
212-600-1902
david.rosen@argotpartners.com

Investor Contact:
Sherri Spear
Argot Partners
212-600-1902
sherri@argotpartners.com

FAQ

What is the date and time of TScan Therapeutics' virtual fireside chat?

The virtual fireside chat will take place on October 5, 2021, at 2:00 p.m. ET.

Who is participating in the TScan Therapeutics event at the Chardan conference?

David Southwell, President and CEO of TScan Therapeutics, will participate in the event.

How can I watch the TScan Therapeutics fireside chat?

You can watch the fireside chat live on the 'Events and Presentations' section of TScan's website.

What therapies is TScan Therapeutics developing?

TScan is developing T-cell receptor therapies like TSC-100 and TSC-101 for hematologic malignancies and multiplexed therapies for solid tumors.

Where can I find a replay of the TScan Therapeutics fireside chat?

An archived replay of the chat will be available on the TScan website after the event.